BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 2385096)

  • 1. PDN-21: possible tumor marker for medullary thyroid carcinoma.
    Takami H; Shikata J; Horie H; Sekine K; Ito K
    J Surg Oncol; 1990 Aug; 44(4):205-7. PubMed ID: 2385096
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluation of sensitive PDN-21 (katacalcin) determination as tumor marker in medullary thyroid carcinoma.
    Blind E; Raue F; Klaiber T; Zink A; Schroth J; Buhr H; Ziegler R
    J Endocrinol Invest; 1992 Feb; 15(2):93-8. PubMed ID: 1569295
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Calcitonin and PDN-21 as tumour markers in MEN-2 family screening for medullary thyroid carcinoma.
    Schifter S
    Eur J Cancer; 1992; 28(2-3):341-5. PubMed ID: 1350454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diagnostic evaluation of measurements of carboxyl-terminal flanking peptide (PDN-21) of the human calcitonin gene in human serum.
    Ittner J; Dambacher MA; Born W; Ketelslegers JM; Buysschaert M; Albert PM; Lambert AE; Fischer JA
    J Clin Endocrinol Metab; 1985 Dec; 61(6):1133-7. PubMed ID: 3902867
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Measurement of serum PDN-21 (Katacalcin) levels by radioimmunoassay in patients with various thyroid diseases.
    Takami H
    Exp Clin Endocrinol; 1994; 102(5):370-3. PubMed ID: 7867699
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PDN-21 (katacalcin) and chromogranin A: tumor markers for medullary thyroid carcinoma.
    Raue F; Blind E; Grauer A
    Henry Ford Hosp Med J; 1992; 40(3-4):296-8. PubMed ID: 1483876
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Circulating procalcitonin and cleavage products in septicaemia compared with medullary thyroid carcinoma.
    Ittner L; Born W; Rau B; Steinbach G; Fischer JA
    Eur J Endocrinol; 2002 Dec; 147(6):727-31. PubMed ID: 12457446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Calcitonin gene-related peptide as a tumor marker for medullary thyroid carcinoma.
    Takami H; Ito K
    Int Surg; 1992; 77(3):181-5. PubMed ID: 1399365
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Utility of proGRP as a tumor marker in the medullary thyroid carcinoma.
    Parra-Robert M; Orois A; Augé JM; Halperin I; Filella X; Molina R
    Clin Chem Lab Med; 2017 Mar; 55(3):441-446. PubMed ID: 27754959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Salmon and human calcitonin-like peptides in man.
    Tobler PH; Tschopp FA; Dambacher MA; Fischer JA
    Clin Endocrinol (Oxf); 1984 Mar; 20(3):253-9. PubMed ID: 6723077
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A preliminary evaluation of calcitonin and PDN-21 as tumor markers for lung cancer. EORTC Lung Cancer Working Party.
    Body JJ; Dumon JC; Sculier JP; Dabouis G; Lacroix H; Libert P; Richez M; Bureau G; Mommen P; Raymakers N
    Henry Ford Hosp Med J; 1989; 37(3-4):190-3. PubMed ID: 2639133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Calcitonin levels by ECLIA correlate well with RIA values in higher range but are affected by sex, TgAb, and renal function in lower range.
    Ito Y; Kaneko H; Sasaki Y; Ohana N; Ichijo M; Furuya F; Suzuki S; Suzuki S; Shimura H
    Endocr J; 2020 Jul; 67(7):759-770. PubMed ID: 32269183
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chromogranin A as tumor marker in medullary thyroid carcinoma.
    Blind E; Schmidt-Gayk H; Sinn HP; O'Connor DT; Raue F
    Thyroid; 1992; 2(1):5-10. PubMed ID: 1356053
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cosecretion of calcitonin gene products: studies with a C18 cartridge extraction method for human plasma PDN-21 (katacalcin).
    Hurley DL; Katz HH; Tiegs RD; Calvo MS; Barta JR; Heath H
    J Clin Endocrinol Metab; 1988 Mar; 66(3):640-4. PubMed ID: 3350911
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Procalcitonin: a marker for the diagnosis and follow-up of patients with medullary thyroid carcinoma.
    Algeciras-Schimnich A; Preissner CM; Theobald JP; Finseth MS; Grebe SK
    J Clin Endocrinol Metab; 2009 Mar; 94(3):861-8. PubMed ID: 19088163
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of sporadic medullary thyroid carcinoma: the importance of routine measurement of serum calcitonin in the diagnostic evaluation of thyroid nodules.
    Rieu M; Lame MC; Richard A; Lissak B; Sambort B; Vuong-Ngoc P; Berrod JL; Fombeur JP
    Clin Endocrinol (Oxf); 1995 May; 42(5):453-60. PubMed ID: 7621562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Calcitonin and procalcitonin in patients with medullary thyroid cancer or bacterial infection.
    Kaczka K; Mikosiński S; Fendler W; Celnik A; Pomorski L
    Adv Clin Exp Med; 2012; 21(2):169-78. PubMed ID: 23214280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Radioimmunoassay of plasma calcitonin gene-related peptide (CGRP) levels in patients with endocrine tumor].
    Takami H; Shikata J; Horie H; Horiuchi J; Sakurai H; Ito K
    Gan To Kagaku Ryoho; 1989 Jun; 16(6):2219-25. PubMed ID: 2786708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Spuriously elevated plasma calcitonin in a patient with a thyroid nodule not associated with medullary thyroid carcinoma.
    Lamb EJ; Heddle RM; Ellis A
    Postgrad Med J; 1999 May; 75(883):289-90. PubMed ID: 10533634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determination of plasma calcitonin gene-related peptide concentrations by a new immunochemiluminometric assay in normal persons and patients with medullary thyroid carcinoma and other neuroendocrine tumors.
    Carter WB; Taylor RL; Kao PC; Heath H
    J Clin Endocrinol Metab; 1991 Feb; 72(2):327-35. PubMed ID: 1991803
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.